These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 35691607)

  • 41. Recent progress of antiviral therapy for coronavirus disease 2019.
    Zhao M; Zhang J; Li H; Luo Z; Ye J; Xu Y; Wang Z; Ye D; Liu J; Li D; Wang M; Wan J
    Eur J Pharmacol; 2021 Jan; 890():173646. PubMed ID: 33190802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
    Mallhi TH; Ahmad A; Butt MH; Misbah S; Khan YH; Alotaibi NH
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):124-128. PubMed ID: 33115586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiviral treatment selection for SARS-CoV-2 pneumonia.
    Bassetti M; Corcione S; Dettori S; Lombardi A; Lupia T; Vena A; De Rosa FG; Gori A; Giacobbe DR
    Expert Rev Respir Med; 2021 Aug; 15(8):985-992. PubMed ID: 33962524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Meo SA; Klonoff DC; Akram J
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A global treatments for coronaviruses including COVID-19.
    Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
    J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An update of anti-viral treatment of COVID-19.
    Şimşek-Yavuz S; Komsuoğlu Çelikyurt FI
    Turk J Med Sci; 2021 Dec; 51(SI-1):3372-3390. PubMed ID: 34391321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection.
    Di Perri G
    Infez Med; 2020 Jun; 28(suppl 1):52-56. PubMed ID: 32532939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Zequn Z; Yujia W; Dingding Q; Jiangfang L
    Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. COVID-19 in Children: Clinical Approach and Management.
    Sankar J; Dhochak N; Kabra SK; Lodha R
    Indian J Pediatr; 2020 Jun; 87(6):433-442. PubMed ID: 32338347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
    More SA; Patil AS; Sakle NS; Mokale SN
    Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Atmar RL; Finch N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
    Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
    Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.
    Saha T; Quiñones-Mateu ME; Das SC
    Int J Pharm; 2022 Aug; 624():122042. PubMed ID: 35868481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro.
    Zhang L; Liu J; Cao R; Xu M; Wu Y; Shang W; Wang X; Zhang H; Jiang X; Sun Y; Hu H; Li Y; Zou G; Zhang M; Zhao L; Li W; Guo X; Zhuang X; Yang XL; Shi ZL; Deng F; Hu Z; Xiao G; Wang M; Zhong W
    Virol Sin; 2020 Dec; 35(6):776-784. PubMed ID: 32910347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.
    Dash P; Mohapatra S; Ghosh S; Nayak B
    Front Pharmacol; 2020; 11():590154. PubMed ID: 33815095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application.
    Uddin E; Islam R; Ashrafuzzaman ; Bitu NA; Hossain MS; Islam AN; Asraf A; Hossen F; Mohapatra RK; Kudrat-E-Zahan M
    Curr Drug Res Rev; 2021; 13(3):184-202. PubMed ID: 34126913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug treatments for covid-19: living systematic review and network meta-analysis.
    Siemieniuk RA; Bartoszko JJ; Zeraatkar D; Kum E; Qasim A; Martinez JPD; Izcovich A; Lamontagne F; Han MA; Agarwal A; Agoritsas T; Azab M; Bravo G; Chu DK; Couban R; Devji T; Escamilla Z; Foroutan F; Gao Y; Ge L; Ghadimi M; Heels-Ansdell D; Honarmand K; Hou L; Ibrahim Q; Khamis A; Lam B; Mansilla C; Loeb M; Miroshnychenko A; Marcucci M; McLeod SL; Motaghi S; Murthy S; Mustafa RA; Pardo-Hernandez H; Rada G; Rizwan Y; Saadat P; Switzer C; Thabane L; Tomlinson G; Vandvik PO; Vernooij RW; Viteri-García A; Wang Y; Yao L; Zhao Y; Guyatt GH; Brignardello-Petersen R
    BMJ; 2020 Jul; 370():m2980. PubMed ID: 32732190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
    Apaydın ÇB; Çınar G; Cihan-Üstündağ G
    Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.